Skip to main content
Top
Published in: International Urology and Nephrology 2/2011

01-06-2011 | Nephrology – Original Paper

Hypovitaminosis D and insulin resistance in peritoneal dialysis patients

Authors: Mehmet E. Bindal, Hulya Taskapan

Published in: International Urology and Nephrology | Issue 2/2011

Login to get access

Abstract

Aim

An association between hypovitaminosis D and insulin resistance has been highlighted. Effects of vitamin D are not only mediated via the vitamin D receptors by active vitamin D metabolites, but 25(OH)D3 also acts through VDR-independent pathways directly. It was reported that acute and chronic intravenous 1,25-dihydroxycholecalciferol therapy corrects insulin resistance in dialysis patients. There are no studies in patients on dialysis which evaluated relationship between 25(OH)D levels and insulin resistance. The aim of this study was to evaluate relationship between serum 25 (OH) D levels and insulin resistance in nondiabetic patients on peritoneal dialysis (PD).

Material methods

We studied 53 nondiabetic patients on PD and in 25 age-, gender- and body mass index-matched healthy controls. Insulin resistance was evaluated by the homeostasis model assessment method (HOMA-IR) using fasting glucose and insulin levels. Vitamin D deficiency was defined if 25(OH)D3 levels are equal to or less to 15 ng/ml.

Results

Mean HOMA-IR index in patients on PD (3.1 ± 3.3) was significantly higher than those of controls (1.7 ± 1.9) (P < 0.05). The mean 25 (OH)D level in PD patients was (21.1 ± 19.0 ng/ml) lower than those of controls (27.5 ± 9.3 ng/ml) (P < 0.05). Twenty-five (47.2%) PD patients had vitamin D deficiency [mean 25(OH)D: 7.2 ± 3.2 ng/ml], and in 28 of them (52.8%) 25 (OH)D levels were more than 15 ng/ml (mean 33.5 ± 18.7 ng/ml). In PD patients with vitamin D deficiency, mean HOMA-IR index (4.2 ± 3.8) was significantly higher than that of PD patients whose 25 (OH)D levels were more than 15 ng/ml (2.2 ± 2.4) (P < 0.05). Twenty-one (84.0%) of PD patients with vitamin D deficiency, and 22 (78.6%) PD patients whose 25 (OH)D levels were more than 15 ng/mL have been receiving active vitamin D compounds for parathyroid hormone (PTH) control (P > 0.05). There was no significant difference between two PD groups according to mean duration of PD, age, gender, PTH, serum calcium, phosphorus, percentage of fat, and body mass index. There was a negative correlation between HOMA-IR index and 25 (OH)D levels in PD patients (r: −0,368, P < 0,05). In multiple regression analyses, the independent predictors of HOMA-IR index were 25(OH)D3 levels, duration of dialysis, and percentage of fat (measured by bioelectrical impedance) in PD patients.

Conclusion

Our findings show a negative correlation of 25(OH)D levels with insulin resistance in PD patients. PD patients with hypovitaminosis D are at higher risk of insulin resistance even if they are on treatment with active vitamin D for PTH control. Further studies are required to explore the relation between vitamin D deficiency and insulin resistance in PD patients.
Literature
1.
go back to reference Tangpricha V, Pearce EN, Chen TC et al (2002) Vitamin D insufficiency among free-living healthy young adults. Am J Med 112(8):659–662PubMedCrossRef Tangpricha V, Pearce EN, Chen TC et al (2002) Vitamin D insufficiency among free-living healthy young adults. Am J Med 112(8):659–662PubMedCrossRef
2.
go back to reference Van der Wielen RP, Lowik MR, Van den Berg H et al (1995) Serum vitamin D concentrations among elderly people in Europe. Lancet 346:207–210PubMedCrossRef Van der Wielen RP, Lowik MR, Van den Berg H et al (1995) Serum vitamin D concentrations among elderly people in Europe. Lancet 346:207–210PubMedCrossRef
3.
go back to reference Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79(5):820PubMed Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79(5):820PubMed
4.
go back to reference Mertens PR, Müller R (2009) Vitamin D and cardiovascular risk. Int Urol Nephrol (Epub ahead of print) Mertens PR, Müller R (2009) Vitamin D and cardiovascular risk. Int Urol Nephrol (Epub ahead of print)
5.
go back to reference Neves PL, Malho A, Cabrita A, Pinho A, Baptista A, Morgado E, Faísca M, Carrasqueira H, Silva AP (2009) Statins and vitamin D: a friendly association in pre-dialysis patients. Int Urol Nephrol (Epub ahead of print) Neves PL, Malho A, Cabrita A, Pinho A, Baptista A, Morgado E, Faísca M, Carrasqueira H, Silva AP (2009) Statins and vitamin D: a friendly association in pre-dialysis patients. Int Urol Nephrol (Epub ahead of print)
6.
go back to reference Rammos G, Tseke P, Ziakka S (2008) Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol 40(2):419–426 (review)PubMedCrossRef Rammos G, Tseke P, Ziakka S (2008) Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol 40(2):419–426 (review)PubMedCrossRef
7.
go back to reference Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) Vitamin D(3) in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38(2):323–329PubMedCrossRef Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) Vitamin D(3) in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38(2):323–329PubMedCrossRef
8.
go back to reference Taskapan H, Ersoy FF, Passadakis P, Tam P, Memmos D, Katopodis K, Ozener C, Akcicek F, Camsarı T, Ates K, Ataman R, Vlachojannis JG, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylalı I, Arınsoy T, Stathakis Ch, Yavuz M, Tsakiris D, Dimitriades A, Yılmaz ME, Gültekin M, Karayalçın B, Polat N, Oreopoulos DG (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol Clin Nephrol 66(4):247–255 Taskapan H, Ersoy FF, Passadakis P, Tam P, Memmos D, Katopodis K, Ozener C, Akcicek F, Camsarı T, Ates K, Ataman R, Vlachojannis JG, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylalı I, Arınsoy T, Stathakis Ch, Yavuz M, Tsakiris D, Dimitriades A, Yılmaz ME, Gültekin M, Karayalçın B, Polat N, Oreopoulos DG (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol Clin Nephrol 66(4):247–255
9.
go back to reference Taskapan H, Ersoy FF, Passadakis P, Tam P, Memmos D, Katopodis K, Ozener C, Akcicek F, Camsarı T, Ates K, Ataman R, Vlachojannis JG, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylalı I, Arınsoy T, Stathakis Ch, Yavuz M, Tsakiris D, Dimitriades A, Yılmaz ME, Gültekin M, Karayalçın B, Polat N, Oreopoulos DG (2005) Body pain during daily activities in patients on peritoneal dialysis. Dial Transplant 2:58–72 Taskapan H, Ersoy FF, Passadakis P, Tam P, Memmos D, Katopodis K, Ozener C, Akcicek F, Camsarı T, Ates K, Ataman R, Vlachojannis JG, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylalı I, Arınsoy T, Stathakis Ch, Yavuz M, Tsakiris D, Dimitriades A, Yılmaz ME, Gültekin M, Karayalçın B, Polat N, Oreopoulos DG (2005) Body pain during daily activities in patients on peritoneal dialysis. Dial Transplant 2:58–72
10.
go back to reference Scragg R, Sowers M, Bell C (2004) Serum 25-Hydroxyvitamin D, Diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813–2818PubMedCrossRef Scragg R, Sowers M, Bell C (2004) Serum 25-Hydroxyvitamin D, Diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813–2818PubMedCrossRef
11.
go back to reference DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J (1981) Insulin resistance in uremia. J Clin Invest 67:563–568PubMedCrossRef DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J (1981) Insulin resistance in uremia. J Clin Invest 67:563–568PubMedCrossRef
12.
go back to reference Pittas AG, Harris SS, Stark PC, Dawson-Hughes B (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of ınflammation in nondiabetic adults. Diabetes Care 30:980–986PubMedCrossRef Pittas AG, Harris SS, Stark PC, Dawson-Hughes B (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of ınflammation in nondiabetic adults. Diabetes Care 30:980–986PubMedCrossRef
13.
go back to reference Mak RHK (1992) Amelioration of hypertension and insulin resistance by 1, 25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 6:345–348PubMedCrossRef Mak RHK (1992) Amelioration of hypertension and insulin resistance by 1, 25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 6:345–348PubMedCrossRef
14.
go back to reference Mak RHK (1992) Intravenous 1, 25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41:1049–1054PubMedCrossRef Mak RHK (1992) Intravenous 1, 25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41:1049–1054PubMedCrossRef
15.
go back to reference Türk S, Yeksan M, Tamer N, Gürbilek M, Erdogan Y, Erkul Ï (1992) Effect of 1, 25 (OH)2 D3 treatment on glucose intolerance in uraemia. Nephrol Dial Transplant 7:1207–1212PubMed Türk S, Yeksan M, Tamer N, Gürbilek M, Erdogan Y, Erkul Ï (1992) Effect of 1, 25 (OH)2 D3 treatment on glucose intolerance in uraemia. Nephrol Dial Transplant 7:1207–1212PubMed
16.
go back to reference Gunal AI, Celìker H, Celebì H, Ustundag B, Gunal SY (1997) Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin Nephrol 48:109–113PubMed Gunal AI, Celìker H, Celebì H, Ustundag B, Gunal SY (1997) Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin Nephrol 48:109–113PubMed
17.
go back to reference Lin S, Lin Y, Lu K, Diang L, Chyr S, Liao W, Shieh S (1994) Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci 87:533–538PubMed Lin S, Lin Y, Lu K, Diang L, Chyr S, Liao W, Shieh S (1994) Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci 87:533–538PubMed
18.
go back to reference Mak RHK (1998) 1, 25-dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353–1357PubMedCrossRef Mak RHK (1998) 1, 25-dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353–1357PubMedCrossRef
19.
go back to reference Strózecki P, Kretowicz M, Odrow-Sypniewska G, Manitius J (2004) The ınfluence of ıntravenous 1, 25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren Fail 26:345–348PubMedCrossRef Strózecki P, Kretowicz M, Odrow-Sypniewska G, Manitius J (2004) The ınfluence of ıntravenous 1, 25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren Fail 26:345–348PubMedCrossRef
20.
go back to reference Blair D, Byham-Gray L, Lewis E, McCaffrey S (2008) Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18:375–382PubMedCrossRef Blair D, Byham-Gray L, Lewis E, McCaffrey S (2008) Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18:375–382PubMedCrossRef
21.
go back to reference Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R (1995) Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47:200–206PubMedCrossRef Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R (1995) Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47:200–206PubMedCrossRef
22.
go back to reference Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013PubMedCrossRef Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013PubMedCrossRef
23.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
24.
go back to reference Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. 338(13):867–872 Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. 338(13):867–872
25.
go back to reference Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri M (2008) Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis Transpl 19(6):942–947PubMed Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri M (2008) Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis Transpl 19(6):942–947PubMed
27.
go back to reference Smith EL, Walworth ND, Holick MF (1986) Effect of 1, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86:709–714PubMedCrossRef Smith EL, Walworth ND, Holick MF (1986) Effect of 1, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86:709–714PubMedCrossRef
28.
go back to reference Dusso AS, Finch J, Brown A et al (1991) Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72:157–164PubMedCrossRef Dusso AS, Finch J, Brown A et al (1991) Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72:157–164PubMedCrossRef
29.
go back to reference Stumpf WE, Sar M, Reid FA et al (1979) Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 206:1188–1190PubMedCrossRef Stumpf WE, Sar M, Reid FA et al (1979) Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 206:1188–1190PubMedCrossRef
30.
go back to reference Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368–375PubMedCrossRef Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368–375PubMedCrossRef
31.
go back to reference Lambert PW, Stern PH, Avioli RC et al (1982) Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69:722–725PubMedCrossRef Lambert PW, Stern PH, Avioli RC et al (1982) Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69:722–725PubMedCrossRef
32.
go back to reference Pettifor JM, Bikle DD, Cavaleros M et al (1995) Serum levels of free 1, 25-dihydroxyvitamin D in vitamin toxicity. Ann Intern Med 122(7):5111–5133 Pettifor JM, Bikle DD, Cavaleros M et al (1995) Serum levels of free 1, 25-dihydroxyvitamin D in vitamin toxicity. Ann Intern Med 122(7):5111–5133
33.
go back to reference Guilherme A, Virbasius JV, Puri V et al (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367–377PubMedCrossRef Guilherme A, Virbasius JV, Puri V et al (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367–377PubMedCrossRef
34.
go back to reference Ozcan U, Cao Q, Yilmaz E et al (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457–461PubMedCrossRef Ozcan U, Cao Q, Yilmaz E et al (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457–461PubMedCrossRef
35.
go back to reference Trirogoff ML, Shintani A, Himmelfarb J et al (2007) Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3–4 chronic kidney disease patients. Am J Clin Nutr 86:1642–1648PubMed Trirogoff ML, Shintani A, Himmelfarb J et al (2007) Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3–4 chronic kidney disease patients. Am J Clin Nutr 86:1642–1648PubMed
36.
go back to reference Sanches FM, Avesani CM, Kamimura MA et al (2008) Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 52(1):66–73PubMedCrossRef Sanches FM, Avesani CM, Kamimura MA et al (2008) Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 52(1):66–73PubMedCrossRef
37.
go back to reference Axelsson J, Rashid Qureshi A, Suliman ME et al (2004) Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80:1222–1229PubMed Axelsson J, Rashid Qureshi A, Suliman ME et al (2004) Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80:1222–1229PubMed
Metadata
Title
Hypovitaminosis D and insulin resistance in peritoneal dialysis patients
Authors
Mehmet E. Bindal
Hulya Taskapan
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2011
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9813-9

Other articles of this Issue 2/2011

International Urology and Nephrology 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine